Approved September 2010
relapsing multiple sclerosis
Gilenya is a sphingosine 1-phosphate receptor modulator. The exact mechanism is unknown, but Gilenya is thought to work by reducing the immune system's attack on the central nervous system by retaining certain white blood cells (lymphocytes) in the lymph nodes.
Gilenya is specifically indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Gilenya is supplied as a capsule designed for oral administration. The recommended initial dose is 0.5 mg orally once daily, with or without food.
The FDA approval of Gilenya was based on two clinical studies.
This 2-year randomized, double-blind, placebo-controlled study in 1,272 patients with RRMS who had not received any interferon-beta or glatiramer acetate for at least the previous 3 months and had not received any natalizumab for at least the previous 6 months. The subjects received Gilenya 0.25mg, 1.25mg or placebo for up to 24 months. The primary endpoint was the annual relapse rate. The 1.25 mg dose resulted in no additional benefit over the 0.5 mg dose. Results are as follows: Annualized relapse rate 0.18 for Gilenya 0.5mg vs. 0.40 for placebo (p<0.001). Percentage of patients without relapse: 70% for Gilenya 0.5mg vs. 46% for placebo (p<0.001). The mean (median) number of new or newly enlarging T2 lesions over 24 months was 2.5 for Gilenya 0.5mg vs. 9.8 for placebo (p<0.001).
This 1-year randomized, double-blind, double-dummy, active-controlled study enrolled 1,292 subjects with RRMS who had not received any natalizumab in the previous 6 months. The subjects were randomized to receive Gilenya 0.5 mg, 1.25 mg or interferon beta-1a, 30 micrograms via the intramuscular route (IM) once weekly for up to 12 months. The annualized relapse rate was significantly lower in patients treated with Gilenya 0.5 mg than in patients who received interferon beta-1a IM. The 1.25 mg dose resulted in no additional benefit over the Gilenya 0.5 mg dose. The results are as follows: Annualized relapse rate 0.16 for Gilenya 0.5mg vs. 0.33 for Interferon beta-1a (p<0.001). Percentage of patients without relapse: 83% for Gilenya 0.5mg vs. 70% for Interferon beta-1a (p<0.001). The mean (median) number of new or newly enlarging T2 lesions over 24 months was 1.6 for Gilenya 0.5mg vs. 2.6 for IFN beta (p=0.002).
Adverse events associated with the use of Gilenya may include, but are not limited to, the following:
Gilenya is a sphingosine 1-phosphate receptor modulator and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
For additional information regarding Gilenya or relapsing multiple sclerosis please visit the Gilenya web page.
The Gilenya (fingolimod) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.